Kefir, a fermented milk beverage rich in probiotics, has been investigated for its potential benefits in managing colitis, particularly ulcerative colitis and experimental models of inflammatory bowel disease (IBD). Several animal studies have shown that kefir administration may reduce inflammation, improve gut barrier function, and modulate immune responses in chemically induced colitis models. These effects are thought to be due to the diverse microbiota present in kefir, including Lactobacillus, Bifidobacterium, and yeast species, which can help restore balance to the intestinal microbiome and reduce the overactive immune response characteristic of colitis.

Human data are more limited, but small pilot studies and anecdotal reports suggest that kefir may be safe and potentially beneficial as an adjunct therapy in IBD patients by improving gastrointestinal symptoms and possibly reducing disease activity. However, these studies are often small, lack rigorous controls, or are not blinded, making it difficult to draw firm conclusions. Major gastroenterological societies do not currently recommend kefir as a primary or proven therapy for colitis due to the lack of large, high-quality clinical trials.

In summary, while there is a scientific rationale and some preclinical and preliminary human evidence supporting the use of kefir for colitis, the overall quality and quantity of evidence is limited. Its use is best considered as a complementary approach rather than a replacement for standard medical therapies.